These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 39039883

  • 1. [Nusinersen in the treatment of 4 children with presymptomatic spinal muscular atrophy].
    Feng YJ, Yu YC, Yan Y, Xu L, Zhao CY, Sheng GX, Chen C, Yang RL, Chen TT, Gao F, Mao SS.
    Zhonghua Er Ke Za Zhi; 2024 Aug 02; 62(8):786-788. PubMed ID: 39039883
    [Abstract] [Full Text] [Related]

  • 2. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS, Born AP, Boesen MS.
    Dan Med J; 2020 Aug 07; 67(9):. PubMed ID: 32800069
    [Abstract] [Full Text] [Related]

  • 3. One Year of Newborn Screening for SMA - Results of a German Pilot Project.
    Vill K, Kölbel H, Schwartz O, Blaschek A, Olgemöller B, Harms E, Burggraf S, Röschinger W, Durner J, Gläser D, Nennstiel U, Wirth B, Schara U, Jensen B, Becker M, Hohenfellner K, Müller-Felber W.
    J Neuromuscul Dis; 2019 Aug 07; 6(4):503-515. PubMed ID: 31594245
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study.
    Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, Ropars J, Chouchane M, Cuppen I, Hughes I, Illingworth M, Marini-Bettolo C, Rambaud J, Taytard J, Annoussamy M, Scoto M, Gidaro T, Servais L.
    Neurology; 2018 Oct 02; 91(14):e1312-e1318. PubMed ID: 30158155
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
    Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Tauscher-Wisniewski S, McGill BE, Macek TA.
    Nat Med; 2022 Jul 02; 28(7):1381-1389. PubMed ID: 35715566
    [Abstract] [Full Text] [Related]

  • 9. [Experience of the treatment of spinal muscular atrophy type 3 Kugelberg-Welander with Nusinersen].
    Shchepankevich LA, Ushkalenko VK, Dolotov KA, Maksimova YV, Veretelnikov IA, Taneeva EV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024 Jul 02; 124(4):153-158. PubMed ID: 38676690
    [Abstract] [Full Text] [Related]

  • 10. Outcomes in type 1 spinal muscular atrophy on nusinersen: A single center experience.
    Kaltman J, Kern-Smith E, Zhang C, Figueroa J, Ritchey M, Razdan R, Verma S.
    Clin Neurophysiol; 2020 Dec 02; 131(12):2793-2794. PubMed ID: 33130439
    [No Abstract] [Full Text] [Related]

  • 11. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
    Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA.
    Nat Med; 2022 Jul 02; 28(7):1390-1397. PubMed ID: 35715567
    [Abstract] [Full Text] [Related]

  • 12. Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy.
    Lee BH, Waldrop MA, Connolly AM, Ciafaloni E.
    Muscle Nerve; 2021 Aug 02; 64(2):153-155. PubMed ID: 33959970
    [Abstract] [Full Text] [Related]

  • 13. Managing pregnancy in a spinal muscular atrophy type III patient in Indonesia: a case report.
    Setyaningrum CTS, Harahap ISK, Nurputra DK, Rachman IT, Harahap NIF.
    J Med Case Rep; 2022 Jan 16; 16(1):14. PubMed ID: 35033190
    [Abstract] [Full Text] [Related]

  • 14. Controversy over Werdnig-Hoffmann disease and multiple system atrophy.
    Chou SM.
    Curr Opin Neurol; 1993 Dec 16; 6(6):861-4. PubMed ID: 8293160
    [No Abstract] [Full Text] [Related]

  • 15. [Spinal muscular atrophy : Time for newborn screening?].
    Vill K, Blaschek A, Schara U, Kölbel H, Hohenfellner K, Harms E, Olgemöller B, Walter MC, Müller-Felber W.
    Nervenarzt; 2017 Dec 16; 88(12):1358-1366. PubMed ID: 29101527
    [Abstract] [Full Text] [Related]

  • 16. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A, Behrens M, Dörnbrack K, Tassoni A, Stein S, Vogt S, Zöller D, Bernert G, Hagenacker T, Schara-Schmidt U, Schwersenz I, Walter MC, Baumann M, Baumgartner M, Deschauer M, Eisenkölbl A, Flotats-Bastardas M, Hahn A, Horber V, Husain RA, Illsinger S, Johannsen J, Köhler C, Kölbel H, Müller M, von Moers A, Schlachter K, Schreiber G, Schwartz O, Smitka M, Steiner E, Stögmann E, Trollmann R, Vill K, Weiß C, Wiegand G, Ziegler A, Lochmüller H, Kirschner J, SMArtCARE study group.
    Brain; 2023 Feb 13; 146(2):668-677. PubMed ID: 35857854
    [Abstract] [Full Text] [Related]

  • 17. Measurement of muscle strength with a handheld dynamometer in patients with chronic spinal muscular atrophy.
    Febrer A, Rodriguez N, Alias L, Tizzano E.
    J Rehabil Med; 2010 Mar 13; 42(3):228-31. PubMed ID: 20411217
    [Abstract] [Full Text] [Related]

  • 18. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
    Aartsma-Rus A.
    Nucleic Acid Ther; 2017 Apr 13; 27(2):67-69. PubMed ID: 28346110
    [No Abstract] [Full Text] [Related]

  • 19. Nusinersen (Spinraza) for spinal muscular atrophy.
    Med Lett Drugs Ther; 2017 Mar 27; 59(1517):50-52. PubMed ID: 28323809
    [No Abstract] [Full Text] [Related]

  • 20. Infantile spinal muscular atrophy (SMA).
    Chabrol B, Desguerre I.
    Arch Pediatr; 2020 Dec 27; 27(7S):7S1-7S2. PubMed ID: 33357590
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.